Association of toll‑like receptor 9 expression with prognosis of systemic lupus erythematosus

Yuan,Yi; Zhao,Ling; Ye,Zhuang; Ma,Hongshuang; Wang,Xiaosong; Jiang,Zhenyu

doi:10.3892/etm.2019.7290

Association of toll‑like receptor 9 expression with prognosis of systemic lupus erythematosus

Authors:
- Yi Yuan
- Ling Zhao
- Zhuang Ye
- Hongshuang Ma
- Xiaosong Wang
- Zhenyu Jiang
View Affiliations

Affiliations: Department of Rheumatology and Immunology, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China, Institute of Translational Medicine, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: February 21, 2019 https://doi.org/10.3892/etm.2019.7290
Pages: 3247-3254

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The current study assessed the association between toll‑like receptor 9 (TLR9) and systemic lupus erythematosus (SLE) and subsequently determined the predictive value of TLR9 in assessing the prognosis of SLE. A total of 90 newly diagnosed patients with SLE and 49 healthy control subjects were enrolled in the current study. The expression of TLR9 mRNA was measured in whole blood samples from patients and controls. All patients were followed up for ≥2 years and their clinical parameters were recorded. After 2 years, 30 patients were randomly chosen from patient subgroups with high (n=20) or low (n=10) TLR9 levels and the expression of TLR9 mRNA were measured again. Cox proportional hazards regression was used to identify the risk factors of SLE prognosis. Patients with SLE and high SLE disease activity exhibited significantly increased TLR9 expression (P<0.05). Persistent proteinuria of >0.5 g/day [hazard ratio (HR), 6.314; 95% confidence interval (CI), 2.858‑13.947], C‑reactive protein levels (HR, 1.013; 95% CI, 1.007‑1.019) and high‑TLR9 mRNA expression (HR, 3.852; 95% CI, 1.931‑7.684) were independent risk factors of poor prognosis during a 2‑year follow‑up period, whereas patient treatment with >1 immunosuppressant (HR, 0.374; 95% CI, 0.173‑0.808) was a factor indicating favorable prognosis. Furthermore, the expression of TLR9 mRNA remained high in patients with poor prognosis at the end of a 2‑year follow‑up period but in patients with a favorable prognosis, TLR9 mRNA expression was significantly reduced compared with the levels measured at SLE onset (P<0.0001). Therefore, the expression of TLR9 mRNA in whole blood samples at SLE onset is associated with SLE disease activity and its expression may be used as an indicator of poor prognosis in patients with SLE.

View Figures

View References

1	O'Neill S and Cervera R: Systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 24:841–855. 2010. View Article : Google Scholar : PubMed/NCBI
2	Kasitanon N, Magder LS and Petri M: Predictors of survival in systemic lupus erythematosus. Medicine (Baltimore). 85:147–156. 2006. View Article : Google Scholar : PubMed/NCBI
3	Ward MM, Pyun E and Studenski S: Causes of death in systemic lupus erythematosus. Long-term followup of an inception cohort. Arthritis Rheum. 38:1492–1499. 1995. View Article : Google Scholar : PubMed/NCBI
4	Zen M, Iaccarino L, Gatto M, Bettio S, Nalotto L, Ghirardello A, Punzi L and Doria A: Prolonged remission in Caucasian patients with SLE: Prevalence and outcomes. Ann Rheum Dis. 74:2117–2122. 2015. View Article : Google Scholar : PubMed/NCBI
5	Lloyd W and Schur PH: Immune complexes, complement, and anti-DNA in exacerbations of systemic lupus erythematosus (SLE). Medicine (Baltimore). 60:208–217. 1981. View Article : Google Scholar : PubMed/NCBI
6	Kao AH, Navratil JS, Ruffing MJ, Liu CC, Hawkins D, McKinnon KM, Danchenko N, Ahearn JM and Manzi S: Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus. Arthritis Rheum. 62:837–844. 2010. View Article : Google Scholar : PubMed/NCBI
7	Bootsma H, Spronk PE, Ter Borg EJ, Hummel EJ, de Boer G, Limburg PC and Kallenberg CG: The predictive value of fluctuations in IgM and IgG class anti-dsDNA antibodies for relapses in systemic lupus erythematosus. A prospective long-term observation. Ann Rheum Dis. 56:661–666. 1997. View Article : Google Scholar : PubMed/NCBI
8	Wong CK, Wong PT, Tam LS, Li EK, Chen DP and Lam CW: Activation profile of Toll-like receptors of peripheral blood lymphocytes in patients with systemic lupus erythematosus. Clin Exp Immunol. 159:11–22. 2010. View Article : Google Scholar : PubMed/NCBI
9	Wu O, Chen GP, Chen H, Li XP, Xu JH, Zhao SS, Sheng J, Feng JB, Cai J, Fang XH, et al: The expressions of Toll-like receptor 9 and T-bet in circulating B and T cells in newly diagnosed, untreated systemic lupus erythematosus and correlations with disease activity and laboratory data in a Chinese population. Immunobiology. 214:392–402. 2009. View Article : Google Scholar : PubMed/NCBI
10	Clancy RM, Markham AJ and Buyon JP: Endosomal Toll-like receptors in clinically overt and silent autoimmunity. Immunol Rev. 269:76–84. 2016. View Article : Google Scholar : PubMed/NCBI
11	Means TK, Latz E, Hayashi F, Murali MR, Golenbock DT and Luster AD: Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest. 115:407–417. 2005. View Article : Google Scholar : PubMed/NCBI
12	Papadimitraki ED, Choulaki C, Koutala E, Bertsias G, Tsatsanis C, Gergianaki I, Raptopoulou A, Kritikos HD, Mamalaki C, Sidiropoulos P and Boumpas DT: Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: Implications for the induction and maintenance of the autoimmune process. Arthritis Rheum. 54:3601–3611. 2006. View Article : Google Scholar : PubMed/NCBI
13	Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, Mejía JC, Aydintug AO, Chwalinska-Sadowska H, de Ramón E, et al: Morbidity and mortality in systemic lupus erythematosus during a 10-year period: A comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 82:299–308. 2003. View Article : Google Scholar : PubMed/NCBI
14	Abu-Shakra M, Urowitz MB, Gladman DD and Gough J: Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortality. J Rheumatol. 22:1265–1270. 1995.PubMed/NCBI
15	Abu-Shakra M, Urowitz MB, Gladman DD and Gough J: Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol. 22:1259–1264. 1995.PubMed/NCBI
16	Formiga F, Moga I, Pac M, Mitjavila F, Rivera A and Pujol R: High disease activity at baseline does not prevent a remission in patients with systemic lupus erythematosus. Rheumatology (Oxford). 38:724–727. 1999. View Article : Google Scholar : PubMed/NCBI
17	Hochberg MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 40:17251997. View Article : Google Scholar : PubMed/NCBI
18	Zen M, Bassi N, Nalotto L, Canova M, Bettio S, Gatto M, Ghirardello A, Iaccarino L, Punzi L and Doria A: Disease activity patterns in a monocentric cohort of SLE patients: A seven-year follow-up study. Clin Exp Rheumatol. 30:856–863. 2012.PubMed/NCBI
19	Bombardier C, Gladman DD, Urowitz MB, Caron D and Chang CH: Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 35:630–640. 1992. View Article : Google Scholar : PubMed/NCBI
20	Somerfield SD, Roberts MW and Booth RJ: Double-stranded DNA antibodies: A comparison of four methods of detection. J Clin Pathol. 34:1032–1035. 1981. View Article : Google Scholar : PubMed/NCBI
21	Haugbro K, Nossent JC, Winkler T, Figenschau Y and Rekvig OP: Anti-dsDNA antibodies and disease classification in antinuclear antibody positive patients: The role of analytical diversity. Ann Rheum Dis. 63:386–394. 2004. View Article : Google Scholar : PubMed/NCBI
22	Ng KP, Manson JJ, Rahman A and Isenberg DA: Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus. Arthritis Rheum. 55:900–904. 2006. View Article : Google Scholar : PubMed/NCBI
23	Gladman DD, Urowitz MB and Keystone EC: Serologically active clinically quiescent systemic lupus erythematosus: A discordance between clinical and serologic features. Am J Med. 66:210–215. 1979. View Article : Google Scholar : PubMed/NCBI
24	Nikpour M, Urowitz MB, Ibañez D and Gladman DD: Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. Arthritis Rheum. 61:1152–1158. 2009. View Article : Google Scholar : PubMed/NCBI
25	Tseng CE, Buyon JP, Kim M, Belmont HM, Mackay M, Diamond B, Marder G, Rosenthal P, Haines K, Ilie V and Abramson SB: The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: Findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 54:3623–3632. 2006. View Article : Google Scholar : PubMed/NCBI
26	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
27	Nishimura M and Naito S: Tissue-specific mRNA expression profiles of human toll-like receptors and related genes. Biol Pharm Bull. 28:886–892. 2005. View Article : Google Scholar : PubMed/NCBI
28	Chuang TH and Ulevitch RJ: Cloning and characterization of a sub-family of human toll-like receptors: HTLR7, hTLR8 and hTLR9. Eur Cytokine Netw. 11:372–378. 2000.PubMed/NCBI
29	Rao H, Zeng Q, Liang Y, Xiao C, Xie S and Xu X: Correlation between TLR9 expression and cytokine secretion in the clinical diagnosis of systemic lupus erythematosus. Mediators Inflamm. 2015:7107202015. View Article : Google Scholar : PubMed/NCBI
30	Komatsuda A, Wakui H, Iwamoto K, Ozawa M, Togashi M, Masai R, Maki N, Hatakeyama T and Sawada K: Up-regulated expression of Toll-like receptors mRNAs in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Clin Exp Immunol. 152:482–487. 2008. View Article : Google Scholar : PubMed/NCBI
31	Mortezagholi S, Babaloo Z, Rahimzadeh P, Namdari H, Ghaedi M, Gharibdoost F, Mirzaei R, Bidad K and Salehi E: Evaluation of TLR9 expression on PBMCs and CpG ODN-TLR9 ligation on IFN-α production in SLE patients. Immunopharmacol Immunotoxicol. 39:11–18. 2017. View Article : Google Scholar : PubMed/NCBI
32	Kruse K, Janko C, Urbonaviciute V, Mierke CT, Winkler TH, Voll RE, Schett G, Muñoz LE and Herrmann M: Inefficient clearance of dying cells in patients with SLE: Anti-dsDNA autoantibodies, MFG-E8, HMGB-1 and other players. Apoptosis. 15:1098–1113. 2010. View Article : Google Scholar : PubMed/NCBI
33	Nakano S, Morimoto S, Suzuki J, Nozawa K, Amano H, Tokano Y and Takasaki Y: Role of pathogenic auto-antibody production by Toll-like receptor 9 of B cells in active systemic lupus erythematosus. Rheumatology (Oxford). 47:145–149. 2008. View Article : Google Scholar : PubMed/NCBI
34	Laustrup H, Voss A, Green A and Junker P: SLE disease patterns in a Danish population-based lupus cohort: An 8-year prospective study. Lupus. 19:239–246. 2010. View Article : Google Scholar : PubMed/NCBI
35	Medina-Quiñones CV, Ramos-Merino L, Ruiz-Sada P and Isenberg D: Analysis of complete remission in systemic lupus erythematosus patients over a 32-year period. Arthritis Care Res (Hoboken). 68:981–987. 2016. View Article : Google Scholar : PubMed/NCBI
36	Qiu J, Shao S, Yang G, Shen Z and Zhang Y: Association of Toll like receptor 9 expression with lymph node metastasis in human breast cancer. Neoplasma. 58:251–255. 2011. View Article : Google Scholar : PubMed/NCBI
37	Anders HJ, Vielhauer V, Eis V, Linde Y, Kretzler M, Perez de Lema G, Strutz F, Bauer S, Rutz M, Wagner H, et al: Activation of toll-like receptor-9 induces progression of renal disease in MRL-Fas (lpr) mice. FASEB J. 18:534–536. 2004. View Article : Google Scholar : PubMed/NCBI
38	He B, Qiao X and Cerutti A: CpG DNA induces IgG class switch DNA recombination by activating human B cells through an innate pathway that requires TLR9 and cooperates with IL-10. J Immunol. 173:4479–4491. 2004. View Article : Google Scholar : PubMed/NCBI